OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single‐dose treatment from a phase III, randomized, double‐blind, placebo‐controlled trial (interim analysis)

To evaluate the efficacy and safety of onabotulinumtoxinA (botulinum toxin type A) 100 U in patients with overactive bladder and urinary incontinence.

[1]  Tomomi Kimura,et al.  Persistence and adherence to overactive bladder medications in Japan: A large nationwide real‐world analysis , 2017, International journal of urology : official journal of the Japanese Urological Association.

[2]  J. Juel,et al.  Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003–2012 in a Danish population , 2017, Scandinavian journal of urology.

[3]  V. Nitti,et al.  Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. , 2016, The Journal of urology.

[4]  T. Uchiyama,et al.  Neuromodulation for the Treatment of Lower Urinary Tract Symptoms , 2015, Lower urinary tract symptoms.

[5]  C. Nardo,et al.  OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. , 2013, European urology.

[6]  N. Hinata,et al.  Botulinum toxin type A injection for neurogenic detrusor overactivity: Clinical outcome in Japanese patients , 2013, International journal of urology : official journal of the Japanese Urological Association.

[7]  K. Burgio,et al.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. , 2012, The Journal of urology.

[8]  Y. Homma,et al.  Botulinum toxin A submucosal injection for refractory non‐neurogenic overactive bladder: Early outcomes , 2011, International journal of urology : official journal of the Japanese Urological Association.

[9]  K. Coyne,et al.  Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature , 2011, International journal of clinical practice.

[10]  Rui Pinto,et al.  Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. , 2010, European urology.

[11]  S. de Wachter,et al.  Current Information on Sacral Neuromodulation and Botulinum Toxin Treatment for Refractory Idiopathic Overactive Bladder Syndrome: A Review , 2010, Urologia Internationalis.

[12]  K. Sugaya,et al.  [Economic impact of overactive bladder symptoms in Japan]. , 2008, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[13]  S. Colman,et al.  Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. , 2008, Urology.

[14]  Y. Homma,et al.  Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. , 2006, Urology.

[15]  P. Abrams,et al.  Impact of overactive bladder symptoms on employment, social interactions and emotional well‐being in six European countries , 2006, BJU international.

[16]  Y. Homma,et al.  An epidemiological survey of overactive bladder symptoms in Japan , 2005, BJU international.

[17]  D. Cockayne,et al.  Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. , 2005, The Journal of urology.

[18]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[19]  Magnus Fall,et al.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.

[20]  P. Abrams,et al.  How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study , 2001, BJU international.

[21]  C. Kelleher,et al.  Overactive bladder significantly affects quality of life. , 2000, The American journal of managed care.

[22]  L. Cardozo,et al.  A new questionnaire to assess the quality of life of urinary incontinent women , 1997, British journal of obstetrics and gynaecology.

[23]  Xiaohong Yan,et al.  OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. , 2013, The Journal of urology.

[24]  M. Saito,et al.  Experience with injections of botulinum toxin type A into the detrusor muscle. , 2010, Aktuelle Urologie.

[25]  D. Staskin,et al.  Surgical options for drug-refractory overactive bladder patients. , 2010, Reviews in urology.